Cerebral amyloid angiopathy (CAA) is a condition where protein (called amyloid) builds up in the brain, making blood vessels weak. People with CAA are four times more likely to develop dementia within ...
Approval marks Harrison.ai's second out of three Breakthrough designations to reach marketing authorization, and 9th FDA clearance covering a total of 13 radiological findings.SYDNEY & ...
Even patients with acute ischemic stroke who are delayed in getting to the hospital and already have large cerebral infarcts may derive a benefit from endovascular therapy to remove the clot, ...
The first international trial of an unproven stroke treatment available in the U.S. has concluded that, while harmless, "perispinal" etanercept—injected into the spinal area—is no more effective than ...
Traumatic brain injury (TBI) and ischemic stroke are major public health concerns and leading causes of death and disability worldwide. A research team led by City University of Hong Kong (CityU) ...
Factor XIa inhibitor milvexian did not provide meaningful secondary prevention over dual antiplatelet therapy for stroke survivors, the phase II trial AXIOMATIC-SSP found. In patients with recent ...
South Korea’s MFDS gave regulatory clearance to SK Inc. C&C’s artificial intelligence (AI) solution to diagnose cerebral infarction called Medical Insight+ Brain Infarct on Feb. 22, as a class III ...
A secondary analysis of the phase 2 PACIFIC-STROKE trial showed that asundexian is effective for the secondary prevention of stroke in patients with stroke of atherosclerotic origin, but not those ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results